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Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disease with an unknown 
cause, high prevalence, and no effective therapy. Alterations in gut microbiota com-
position and function have been found in PD, which could influence the gut-brain 
axis. Several mechanisms have been proposed and are investigated to explain the link 
between gut microbiota and PD. In model systems and in individual case reports, 
modulation of gut microbiota has been associated with improvement of PD. A safe 
and effective way of gut microbiota manipulation is fecal microbiota transplant (FMT). 
FMT is used successfully for treatment of recurrent gastrointestinal infections as well 
as other indications. We advocate randomized clinical trials with FMT as a treatment 
option for PD.
Keywords: Parkinson’s disease, gut microbiota, fecal microbiota transplantation, 
clinical trial
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disease which is accompanied by gastroin-
testinal dysfunction in 80% of patients [1]. PD has a high prevalence, affecting almost 2% of 
people over the age of 80 [2] and is currently incurable, although a variety of therapies are 
available to treat the symptoms [3]. In the last decade, the hypothesis has gained support 
that PD starts in the gut and spreads through the sympathetic and parasympathetic nervous 
systems to the substantia nigra and the central nervous system [4, 5]. More recently, it has 
been recognized that these brain-gut axis interactions in PD may be essentially influenced by 
gut microbiota.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
In this opinion paper we want to encourage the design and initiation of clinical trial using 
fecal microbiota transplantation (FMT) as a therapeutic intervention for PD. We first elaborate 
on the evidence for the role of gut microbiota in PD, followed by a short discussion of FMT, 
and conclude with arguments to support the setup of clinical studies.
2. Alterations in gut microbiota composition in PD patients
A causal link between Helicobacter pylori infections and PD has been suggested for a long time 
[6, 7]. Even before the discovery of H. pylori, the connection between PD and gastric ulcers has 
already been reported [8, 9], and it was found that duodenal and gastric ulcers often preceded 
the onset of PD by many (10–20) years. Since then, numerous studies have reported that the 
incidence of small intestinal bacterial overgrowth is higher in PD patients than in healthy 
controls [10–13] that PD patients have higher H. pylori antibody levels [14] and that H. pylori 
infections are more prevalent in PD patients than in control groups [15, 16].
Several recent studies show that PD is also preceded or accompanied by changes in the abun-
dance of other bacterial groups. It thus has been found that PD patients harbor lower con-
centrations of Prevotella bacteria [17–21], and the number of Prevotella bacteria is negatively 
correlated with the severity of PD symptoms [20]. Increased numbers of Enterobacteria are 
found in PD patients [17, 22], and the relative abundance of Enterobacteriaceae is positively 
associated with the severity of postural instability and gait difficulty [20]. In another study, sig-
nificantly altered abundances of the Bifidobacteriaceae, Christensenellaceae, (Tissierellaceae), 
Lachnospiraceae, Lactobacillaceae, Pasteurellaceae, and Verrucomicrobiaceae families were 
found in PD patients [23]. In PD patients, Lactobacillus numbers were found to be higher and 
Clostridium coccoides plus Bacteroides fragilis numbers were lower compared to healthy con-
trols, all contributing to a distinct composition of gut microbiota in PD [23]. Concentrations 
of hydrogen-producing bacteria were also higher in PD patients [24]. It has been suggested 
that cyanobacteria can be a source of neurotoxins that are related to PD [25, 26]. Molecular 
analysis of the gut microbiome has shown that 48 operational taxonomic units (OTU’s) of the 
gastrointestinal microbiota have differential abundancy in PD patients versus healthy con-
trols. Some of these OTUs were significantly related to motor symptoms and depression in PD 
patients. Functional analysis of gut microbiota also shows differences between PD patients 
and controls. Increased urinary indoxyl sulfate, a marker of intestinal dysbiosis, is found in 
PD patients [27].
Besides gut microbiota, microbiota at other ecological niches may also differ. The oral micro-
biota of PD patients and control subjects had differences in beta diversity and abundances of 
individual bacterial taxa [28].
3. Mechanistic link between gut microbiota and PD
Various studies suggest that gut microbiota do not just correlate with PD but that PD 
may actually start within the gut, with gut microbiota as a causative agent. The fact that 
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gastrointestinal dysfunction often precedes motor symptoms by 10–15 years already strongly 
suggests a role for gut microbiota. In addition, epidemiological studies in Sweden show that 
gotomy drastically reduces the risk of developing PD [29, 30], suggesting the nervus vagus 
as vagotomy a route via which PD may travel from the gut to the CNS (see also Figure 1). 
Sampson and co-workers found that fecal microbiota transplants from human PD patients in 
a mouse model of PD enhances physical impairments, compared to microbiota transplants of 
healthy donors [31]; a finding which may indicate that alterations in the human microbiome 
represent a risk factor for PD.
Various mechanisms and mediators have been proposed for the relation between gut micro-
biota and development of PD (Figure 1). PD may be initiated by toxins produced by the 
gut microbiota or because of a failure to produce key essential neuronal dopamine specific 
nutrients or enzymes, which are required by dopamine-producing cells [32]. For example, 
decreased numbers of Prevotella are linked to decreased production of important micronutri-
ents like short chain fatty acids, thiamine and folate [19], whereas gut microbes like Bacillus 
spp. are known to produce dopamine [33]. Cyanobacteria are believed to produce the excito-
toxin β-N-methyl amino-L-alanine (BMAA) which has been found to be increased in the brain 
of PD patients [26].
Since PD is assumed to be characterized by synucleinopathy, another potential mechanism 
may be that alpha-synuclein produced by gut microbiota spreads upwards from the gut along 
vagal nerve fibers [34, 35].
It has also been suggested that gut dysbiosis leads to chronic low-grade inflammation in the 
gut, which may ultimately trigger blood-brain barrier leakage, immune cell activation and 
inflammation, and ultimately neuroinflammation in the CNS [36]. Increased intestinal perme-
ability has been described in PD, resulting in penetration of E. coli in the intestinal mucosa as 
well as oxidative stress and increased enteric α-synuclein levels [37].
A more general explanation which has been suggested is that the composition of the gut 
microbiota changes over the human lifespan, which may play a role in age-related dis-
eases [38].
Figure 1. Potential mechanisms of interaction between gut microbiota and the brain in Parkinson’s disease.
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4. Therapeutic interventions in the microbiome as a treatment option 
for PD
The effect of interventions in the microbiome on PD has been demonstrated in mouse models. 
Administration of the antibiotic minocycline prevents nigrostriatal dopaminergic neurode-
generation in a mouse model of PD [39]. Sampson et al. have reported that antibiotic treat-
ment of gut microbiota ameliorates physical impairment, whereas microbial recolonization, 
or the oral administration of specific microbial metabolites, promotes pathophysiology in a 
mouse model of PD [31].
In addition, a number of recent clinical studies in human patients show that various treatments 
of either gastrointestinal dysfunction or gut microbiota composition have a beneficial effect on 
PD. For example, maintenance laxative usage was associated with apparent stemming of the 
temporal increase in rigidity in PD [40]. PD patients who were treated for Helicobacter pylori 
infections experienced prolonged (2–3 years) improvement of motor symptoms compared to 
a control group [41–43]. Furthermore, H. pylori-positive PD patients have significantly poorer 
clinical scores as compared to H. pylori-negative PD patients [16]. Twelve weeks after treat-
ment of the H. pylori infection, improvements in levodopa onset time and effect duration were 
observed, as well as better scores in motor performance and quality of life measures [16]. A 
single non peer-reviewed case study described a PD patient that became symptom-free after 
receiving a fecal microbiota transplant [44].
Other (non-PD related) effects of gut microbiota composition on the nervous system have also 
been reported. For example, a case report of three MS patients records dramatic improvement 
of neurological functions after fecal microbiota transplantation [45]. Significant improvement 
of myoclonus dystonia symptoms was observed in a female patient after receiving fecal micro-
biota transplantation [46]. Microbiota management via probiotic supplementation significantly 
reduced overall cognitive reactivity to sad mood in healthy participants of a placebo controlled, 
randomized clinical trial [47]. Finally, it has been demonstrated that gut microbiota from 
depressed patients could induce depression-like behavior in microbiota-depleted rats [48].
5. Fecal microbiota transplantation
Given the evidence described above, modification of the gut microbiota could be a valid and 
attractive treatment option for PD. The most powerful way to modify the gut microbiota is 
via a fecal microbiota transplantation (FMT). FMT is a relatively new treatment option for 
gut dysbiosis-related diseases; mainly Clostridium difficile infections, for which it is highly 
successful with cure rates of over 90% [49, 50]. FMT involves transfer of stool (containing both 
microbes and the bioactive molecules they produce) from a healthy donor to a patient (see 
[50] for a review). More recently, the therapy is also offered via orally administered capsules 
containing a screened sample of donor microbiota in freeze-dried form, which makes the 
treatment even safer and less invasive.
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As of December 2017, nine stool banks have been installed worldwide [51]; the most recent 
ones being in Madrid and Hong Kong. One of them, OpenBiome, founded by Harvard and 
MIT microbiologists, also offers treatment via capsules (www.openbiome.org). For the time 
being, the stool banks only offer treatments to patients suffering from recurrent C. difficile 
infections. However, they also cooperate in studies on other diseases. FMT is considered the 
most cost-effective treatment option in the treatment of recurrent C. difficile infections [52].
FMT is a safe treatment, provided it is performed in a clinical setting and with the use of 
screened donor feces. Several clinical studies report mild side effects or no side effects at 
all [49, 53–57]. Even in high-risk groups, FMT was found to be safe: no adverse effects were 
found in cancer patients [58] as well as in solid organ transplant recipients [59]. A review by 
Baxter and Colville [60] on the adverse events associated with FMT concludes that “The vast 
majority of adverse events of FMT appear to be mild, self-limiting and gastrointestinal in 
nature.” As for every new treatment, potential long-term negative effects are unknown.
It is important to note that outside clinical settings, there are risks associated with FMT. There 
is a growing “do it yourself” movement around FMT, where many people are experiment-
ing with FMT as a last resort option for incurable diseases like PD. The Internet is teeming 
with discussion fora on which people exchange the best DIY techniques, which may involve 
kitchen blenders and various pumping devices. In a recent review of information regarding 
FMT on social media, it is concluded that “there is a vast amount of information available 
about FMT through social media that has the potential for causing harm” [61]. Donor screen-
ing does not take place if and when people perform the treatment themselves. This may lead 
to patients being put at risk to infections or perforations as a result of unprofessional treat-
ment. For example, it has been reported that a child developed aspiration pneumonia as a 
result of the entrance of fecal matter in the bronchial system after the parents performed FMT 
without medical supervision [62]. Another case study describes a patient who developed a 
cytomegalovirus infection, after performing home FMT using unscreened donor feces [63]. 
These examples underline the importance of FMT to be provided in a clinical setting under 
controlled conditions.
6. Arguments in favor of an RCT
Given the above considerations, there are strong arguments for initiating a clinical study on 
the effect of FMT on PD patients.
a. FMT could potentially provide a treatment option for a disease that affects millions of peo-
ple worldwide, is currently incurable, and is expected to become more prevalent as a result 
of an aging population. Given the idea that age-related diseases may be related to aging 
of the gut microbiota [38], using material from young donors may be especially beneficial.
b. FMT is considered safe, even in high-risk groups.
c. FMT is inexpensive
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d. Safe, screened donor feces material can easily be obtained via one of the existing stool 
banks. A control group can be treated with autologous feces. Alternatively, OpenBiome 
offers the possibility to assist in designing a setup and provide orally administered 
capsules.
e. The best way to stem the DIY movement and prevent dangerous situations as a result of 
people experimenting with FMT, is to offer a safe and controlled alternative in a hospi-
tal setting or to develop safe protocols for home-administered fecal transplantations in a 
health care setting [49, 56].
So far, only one clinical trial has been initiated (ClinicalTrials.gov Identifier: NCT03026231) 
[64]. However, we argue that more clinical trials are warranted. The argument that the 
mechanism via which microbiota affect PD is still poorly understood [65–67] should not 
block further application of FMT. Aspirin, for example, has been effectively applied for 
centuries before the mechanism was finally elucidated in the 1970s. Likewise, levodopa has 
been used for the treatment of PD for decades before its mechanism was unraveled. It may 
take years before the pathways via which gut microbiota affect the brain are unraveled, 
and meanwhile a potentially promising treatment option remains unexplored. Given the 
relative ease and safety of the treatment and the fact that it is already applied on a routine 
basis to C. difficile patients, including these in high-risk groups like cancer patients or organ 
transplant recipients, we advocate more clinical studies. Moreover, a clinical study on FMT 
in PD could lead to a better understanding of the relation between microbiota and the 
nervous system.
Finally, several authors have already pointed out that FMT is a very promising treatment 
option for PD. As stated by Mulak and Bonaz: “The close relationship between gut dysbio-
sis, intestinal permeability and neurological dysfunction suggests that the gut microbiota 
modification may provide a promising therapeutic option in PD” [68]. Fang also stated that 
“Microbiota-based interventions that play a regulatory role in the gut microflora exhibit ther-
apeutic potential” (for PD) [69]. Finally, Scheperjans in 2016 comments in an opinion article: 
“If this endeavor is successful, we may end up with completely new therapeutic approaches 
that could hopefully turn the ship around toward effective disease modification or even pre-
vention” [70].
It took a long time before FMT was generally accepted as a treatment option for C. difficile 
infections because physicians were skeptical about this “19th century technique” or wary of 
any adverse effects [71]. It is unknown how many people died (or are still dying) unnecessar-
ily from otherwise untreatable C. difficile infections or had their colons removed, while it was 
already known that FMT could cure them. The prognosis has finally changed for the better-
ment for these patients. In 2010, a study on the effect of FMT on recurrent C. difficile infection 
in Amsterdam was prematurely terminated because the data and safety monitoring board of 
the hospital considered it unethical to withhold the treatment from the control group [55]. 
FMT thus is on the way to becoming a standard treatment for recurrent C. difficile infections 
in most developed countries.
Given the fact that FMT is a very promising treatment for PD, is safe, not invasive (especially 
using orally administered capsules) and inexpensive, and people are exposing themselves 
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to risks by performing the treatment themselves without medical supervision, it could be 
argued that not starting a trial on the effect of FMT on PD would be similarly unethical. The 
roadmap is clear, and it now just needs to be taken.
Conflict of interest
The authors have no conflict of interest to declare.
Author details
Inez A. Flameling1* and Ger T. Rijkers1,2,3
*Address all correspondence to: i.flameling@ucr.nl
1 Department of Science, University College Roosevelt, Middelburg, The Netherlands
2 Laboratory for Medical Microbiology and Immunology, St. Antonius Hospital, 
Nieuwegein, The Netherlands
3 Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
References
[1] Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism & Related 
Disorders. 2011 Jan;17(1):10-15. DOI: 10.1016/j.parkreldis.2010.08.003
[2] Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: A 
systematic review and meta-analysis. Movement Disorders. 2014 Nov;29(13):1583-1590. 
DOI: 10.1002/mds.25945
[3] Radhakrishnan DM, Goyal V. Parkinson's disease: A review. Neurology India. 2018 
Mar–Apr;66(Supplement):S26-S35. DOI: 10.4103/0028-3886.226451
[4] Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Björklund T, Wang ZY, Roybon 
L, Melki R, Li JY. Direct evidence of Parkinson pathology spread from the gastroin-
testinal tract to the brain in rats. Acta Neuropathologica. 2014 Dec;128(6):805-820. DOI: 
10.1007/s00401-014-1343-6
[5] Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease--the gut-brain axis 
and environmental factors. Nature Reviews. Neurology. 2015 Nov;11(11):625-636. DOI: 
10.1038/nrneurol.2015.197
[6] Altschuler E. Gastric Helicobacter pylori infection as a cause of idiopathic Parkinson 
disease and non-arteric anterior optic ischemic neuropathy. Medical Hypotheses. 1996 
Nov;47(5):413-414
Fecal Microbiota Transplants as a Treatment Option for Parkinson’s Disease
http://dx.doi.org/10.5772/intechopen.78666
77
[7] Dobbs SM, Dobbs RJ, Weller C, Charlett A. Link between Helicobacter pylori infection and 
idiopathic parkinsonism. Medical Hypotheses. 2000 Aug;55(2):93-98
[8] Schwab RS. Symptomatology and medical treatment of Parkinson's disease. International 
Journal of Neurology. 1961;2:61-75
[9] Strang RR. The association of gastro-duodenal ulceration and Parkinson’s disease. The 
Medical Journal of Australia. 1965 Jun 5;1(23):842-843
[10] Gabrielli M, Bonazzi P, Scarpellini E, Bendia E, Lauritano EC, Fasano A, Ceravolo MG, 
Capecci M, Rita Bentivoglio A, Provinciali L, Tonali PA, Gasbarrini A. Prevalence of 
small intestinal bacterial overgrowth in Parkinson's disease. Movement Disorders. 2011 
Apr;26(5):889-892. DOI: 10.1002/mds.23566
[11] Dobbs RJ, Charlett A, Dobbs SM, Weller C, A Ibrahim MA, Iguodala O, Smee C, Plant JM, 
Lawson AJ, Taylor D, Bjarnason I. Leukocyte-subset counts in idiopathic parkinsonism 
provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. 
A surveillance study. Gut Pathogens. 2012 Oct 19;4(1):12. DOI: 10.1186/1757-4749-4-12
[12] Fasano A, Bove F, Gabrielli M, Petracca M, Zocco MA, Ragazzoni E, Barbaro F, Piano C, 
Fortuna S, Tortora A, Di Giacopo R, Campanale M, Gigante G, Lauritano EC, Navarra 
P, Marconi S, Gasbarrini A, Bentivoglio AR. The role of small intestinal bacterial over-
growth in Parkinson's disease. Movement Disorders. 2013 Aug;28(9):1241-1249. DOI: 
10.1002/mds.25522
[13] Tan AH, Mahadeva S, Thalha AM, Gibson PR, Kiew CK, Yeat CM, Ng SW, Ang SP, Chow 
SK, Tan CT, Yong HS, Marras C, Fox SH, Lim SY. Small intestinal bacterial overgrowth 
in Parkinson's disease. Parkinsonism & Related Disorders. 2014 May;20(5):535-540. DOI: 
10.1016/j.parkreldis.2014.02.019
[14] Dobbs RJ, Charlett A, Dobbs SM, Weller C, Peterson DW. Parkinsonism: Differential age-
trend in Helicobacter pylori antibody. Alimentary Pharmacology & Therapeutics. 2000 
Sep;14(9):1199-1205
[15] Nafisah W, Najman A, Hamizah R, Azmin S, Rabani R, Shah SA, Norlinah MI. High 
prevalence of Helicobacter pylori infection in Malaysian Parkinson's disease patients. 
Journal of Parkinsonism and Restless Legs Syndrome. 2013;3:63-67
[16] Hashim H, Azmin S, Razlan H, Yahya NW, Tan HJ, Manaf MR, Ibrahim NM. Eradication 
of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality 
of life in patients with Parkinson's disease. PLoS One. 2014 Nov 20;9(11):e112330. DOI: 
10.1371/journal.pone.0112330
[17] Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Bürmann J, Faßbender 
K, Schwiertz A, Schäfer KH. Short chain fatty acids and gut microbiota differ between 
patients with Parkinson's disease and age-matched controls. Parkinsonism & Related 
Disorders. 2016 Nov;32:66-72. DOI: 10.1016/j.parkreldis.2016.08.019
Gut Microbiota - Brain Axis78
[18] Cakmak YO. Coffee consumption, smoking, and Parkinson's disease? The beneficial role 
of hydrogen sulfide. Movement Disorders. 2016 Mar;31(3):429. DOI: 10.1002/mds.26526
[19] Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E, Shannon 
KM. Colonic bacterial composition in Parkinson's disease. Movement Disorders. 2015 
Sep;30(10):1351-1360. DOI: 10.1002/mds.26307
[20] Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, 
Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P. Gut microbiota 
are related to Parkinson's disease and clinical phenotype. Movement Disorders. 2015 
Mar;30(3):350-358. DOI: 10.1002/mds.26069
[21] Heintz-Buschart A, Pandey U, Wicke T, Sixel-Döring F, Janzen A, Sittig-Wiegand E, 
Trenkwalder C, Oertel WH, Mollenhauer B, Wilmes P. The nasal and gut microbiome 
in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder. 
Movement Disorders. 2018 Jan;33(1):88-98. DOI: 10.1002/mds.27105
[22] Ghaisas S, Maher J, Kanthasamy A. Gut microbiome in health and disease: Linking the 
microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic 
and neurodegenerative diseases. Pharmacology & Therapeutics. 2016 Feb;158:52-62. 
DOI: 10.1016/j.pharmthera.2015.11.012
[23] Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, 
Peddada SD, Factor SA, Molho E, Zabetian CP, Knight R, Payami H. Parkinson's disease 
and Parkinson's disease medications have distinct signatures of the gut microbiome. 
Movement Disorders. 2017 May;32(5):739-749. DOI: 10.1002/mds.26942
[24] Hasegawa S, Goto S, Tsuji H, Okuno T, Asahara T, Nomoto K, Shibata A, Fujisawa Y, 
Minato T, Okamoto A, Ohno K, Hirayama M. Intestinal dysbiosis and lowered serum 
lipopolysaccharide-binding protein in Parkinson's disease. PLoS One. 2015 Nov 
5;10(11):e0142164. DOI: 10.1371/journal.pone.0142164
[25] Banack SA, Caller TA, Stommel EW. The cyanobacteria derived toxin Beta-N-methylamino-
L-alanine and amyotrophic lateral sclerosis. Toxins (Basel). 2010 Dec;2(12):2837-2850. DOI: 
10.3390/toxins2122837
[26] Brenner SR. Blue-green algae or cyanobacteria in the intestinal micro-flora may produce 
neurotoxins such as Beta-N-Methylamino-L-Alanine (BMAA) which may be related 
to development of amyotrophic lateral sclerosis, Alzheimer's disease and Parkinson-
Dementia-Complex in humans and Equine Motor Neuron disease in horses. Medical 
Hypotheses. 2013 Jan;80(1):103. DOI: 10.1016/j.mehy.2012.10.010
[27] Cassani E, Barichella M, Cancello R, Cavanna F, Iorio L, Cereda E, Bolliri C, Zampella 
Maria P, Bianchi F, Cestaro B, Pezzoli G. Increased urinary indoxyl sulfate (indican): New 
insights into gut dysbiosis in Parkinson's disease. Parkinsonism & Related Disorders. 
2015 Apr;21(4):389-393. DOI: 10.1016/j.parkreldis.2015.02.004
Fecal Microbiota Transplants as a Treatment Option for Parkinson’s Disease
http://dx.doi.org/10.5772/intechopen.78666
79
[28] Pereira PAB, Aho VTE, Paulin L, Pekkonen E, Auvinen P, Scheperjans F. Oral and nasal 
microbiota in Parkinson's disease. Parkinsonism & Related Disorders. 2017 May;38:61-67. 
DOI: 10.1016/j.parkreldis.2017.02.026
[29] Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer 
P, Sørensen HT. Vagotomy and subsequent risk of Parkinson's disease. Annals of 
Neurology. 2015 Oct;78(4):522-529. DOI: 10.1002/ana.24448
[30] Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekbom A, Svenningsson P, 
Chen H, Wirdefeldt K. Vagotomy and Parkinson disease: A Swedish register-based 
matched-cohort study. Neurology. 2017 May 23;88(21):1996-2002. DOI: 10.1212/WNL. 
0000000000003961
[31] Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter 
CE, Rocha S, Gradinaru V, Chesselet MF, Keshavarzian A, Shannon KM, Krajmalnik-
Brown R, Wittung-Stafshede P, Knight R, Mazmanian SK. Gut microbiota regulate 
motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. 2016 Dec 
1;167(6):1469-1480. e12. DOI: 10.1016/j.cell.2016.11.018
[32] Thakur AK, Shakya A, Husain GM, Emerald M, Kumar V. Gut-microbiota and mental 
health: Current and future perspectives. Journal of Pharmacology & Clinical Toxicology. 
2014;2:1016
[33] Eisenhofer G, Aneman A, Friberg P, Hooper D, Fåndriks L, Lonroth H, Hunyady B, 
Mezey E. Substantial production of dopamine in the human gastrointestinal tract. The 
Journal of Clinical Endocrinology and Metabolism. 1997 Nov;82(11):3864-3871
[34] Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL. Alpha-synuclein-
immunopositive myenteric neurons and vagal preganglionic terminals: Autonomic 
pathway implicated in Parkinson's disease? Neuroscience. 2008 May 15;153(3):733-750. 
DOI: 10.1016/j.neuroscience.2008.02.074
[35] Gershanik OS. Does Parkinson's disease start in the gut? Arquivos de Neuro-Psiquiatria. 
2018 Feb;76(2):67-70. DOI: 10.1590/0004-282X20170188
[36] Nair AT, Ramachandran V, Joghee NM, Antony S, Ramalingam G. Gut microbiota dys-
function as reliable non-invasive early diagnostic biomarkers in the pathophysiology of 
Parkinson's disease: A critical review. Journal of Neurogastroenterology and Motility. 
2018 Jan 30;24(1):30-42. DOI: 10.5056/jnm17105
[37] Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, 
Dodiya HB, Keshavarzian A. Increased intestinal permeability correlates with sigmoid 
mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's 
disease. PLoS One. 2011;6(12):e28032. DOI: 10.1371/journal.pone.0028032
[38] Santoro A, Ostan R, Candela M, Biagi E, Brigidi P, Capri M, Franceschi C. Gut micro-
biota changes in the extreme decades of human life: A focus on centenarians. Cellular 
and Molecular Life Sciences. 2018 Jan;75(1):129-148. DOI: 10.1007/s00018-017-2674-y
[39] Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, 
Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM. Minocycline prevents 
Gut Microbiota - Brain Axis80
nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's dis-
ease. Proceedings of the National Academy of Sciences of the United States of America. 
2001 Dec 4;98(25):14669-14674
[40] Augustin AD, Charlett A, Weller C, Dobbs SM, Taylor D, Bjarnason I, Dobbs RJ. 
Quantifying rigidity of Parkinson's disease in relation to laxative treatment: A service 
evaluation. British Journal of Clinical Pharmacology. 2016 Aug;82(2):441-450. DOI: 
10.1111/bcp
[41] Dobbs SM, Dobbs RJ, Weller C, Charlett A, Bjarnason IT, Lawson AJ, Letley D, Harbin 
L, Price AB, Ibrahim MA, Oxlade NL, Bowthorpe J, Leckstroem D, Smee C, Plant JM, 
Peterson DW. Differential effect of Helicobacter pylori eradication on time-trends in brady/
hypokinesia and rigidity in idiopathic parkinsonism. Helicobacter. 2010 Aug;15(4): 
279-294. DOI: 10.1111/j.1523-5378.2010.00768.x
[42] Dobbs SM, Charlett A, Dobbs RJ, Weller C, Iguodala O, Smee C, Lawson AJ, Taylor D, 
Bjarnason I. Antimicrobial surveillance in idiopathic parkinsonism: Indication-specific 
improvement in hypokinesia following Helicobacter pylori eradication and non-specific 
effect of antimicrobials for other indications in worsening rigidity. Helicobacter. 2013 
Jun;18(3):187-196. DOI: 10.1111/hel.12035
[43] Dobbs SM, Dobbs RJ, Weller C, Charlett A, Augustin A, Taylor D, Ibrahim MA, Bjarnason 
I. Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-mor-
bidities: Role of gastrointestinal microbiota. Journal of Neurovirology. 2016 Feb;22(1): 
22-32. DOI: 10.1007/s13365-015-0357-8
[44] Ananthaswamy A. Faecal transplant eases symptoms of Parkinson’s disease. New 
Scientist. 2011;209:8-9
[45] Borody TJ, Campbell J, Torres M, Nowak A, Leis S. Reversal of idiopathic thrombocyto-
penic purpura [ITP] with fecal microbiota transplantation [FMT]. American Journal of 
Gastroenterology. 2011;106:S352
[46] Borody TJ, Rosen DM, Torres M, Campbell J, Nowak A. Myoclonus-dystonia (M-D) 
mediated by GI microbiota diarrhoea treatment improves M-D symptoms. The American 
Journal of Gastroenterology. 2011;106:S352
[47] Steenbergen L, Sellaro R, van Hemert S, Bosch JA, Colzato LS. A randomized controlled 
trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. 
Brain, Behavior, and Immunity. 2015 Aug;48:258-264. DOI: 10.1016/j.bbi.2015.04.003
[48] Kelly JR, Borre Y, O' Brien C, Patterson E, El Aidy S, Deane J, Kennedy PJ, Beers S, Scott 
K, Moloney G, Hoban AE, Scott L, Fitzgerald P, Ross P, Stanton C, Clarke G, Cryan JF, 
Dinan TG. Transferring the blues: Depression-associated gut microbiota induces neu-
robehavioural changes in the rat. Journal of Psychiatric Research. 2016 Nov;82:109-118. 
DOI: 10.1016/j.jpsychires.2016.07.019
[49] Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplanta-
tion for chronic Clostridium difficile infection. Clinical Gastroenterology and Hepatology. 
2010 May;8(5):471-473. DOI: 10.1016/j.cgh.2010.01.007
Fecal Microbiota Transplants as a Treatment Option for Parkinson’s Disease
http://dx.doi.org/10.5772/intechopen.78666
81
[50] Merenstein D, El-Nachef N, Lynch SV. Fecal microbial therapy: Promises and pitfalls. 
Journal of Pediatric Gastroenterology and Nutrition. 2014 Aug;59(2):157-161. DOI: 
10.1097/MPG.0000000000000415
[51] Terveer EM, van Beurden YH, Goorhuis A, Seegers JFML, Bauer MP, van Nood E, 
Dijkgraaf MGW, Mulder CJJ, Vandenbroucke-Grauls CMJE, Verspaget HW, Keller JJ, 
Kuijper EJ. How to: Establish and run a stool bank. Clinical Microbiology and Infection. 
2017 Dec;23(12):924-930. DOI: 10.1016/j.cmi.2017.05.015
[52] Arbel LT, Hsu E, McNally K. Cost-effectiveness of fecal microbiota transplantation in 
the treatment of recurrent Clostridium difficile infection: A literature review. Cureus. 2017 
Aug 23;9(8):e1599. DOI: 10.7759/cureus.1599
[53] Mattila E, Uusitalo-Seppälä R, Wuorela M, Lehtola L, Nurmi H, Ristikankare M, 
Moilanen V, Salminen K, Seppälä M, Mattila PS, Anttila VJ, Arkkila P. Fecal transplanta-
tion, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. 
Gastroenterology. 2012 Mar;142(3):490-496. DOI: 10.1053/j.gastro.2011.11.037
[54] Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H Jr, Cloney D, Kugathasan 
S. Safety, tolerability, and clinical response after fecal transplantation in children and 
young adults with ulcerative colitis. Journal of Pediatric Gastroenterology and Nutrition. 
2013 Jun;56(6):597-601. DOI: 10.1097/MPG.0b013e318292fa0d
[55] van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, 
Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal 
infusion of donor feces for recurrent Clostridium difficile. The New England Journal of 
Medicine. 2013 Jan 31;368(5):407-415. DOI: 10.1056/NEJMoa1205037
[56] Duke PS, Fardy J. Recurrent Clostridium difficile infection treated with home fecal trans-
plantation: A case report. Journal of Medical Case Reports. 2014 Nov 28;8:393. DOI: 
10.1186/1752-1947-8-393
[57] Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, Kheradman R, Heuman D, Wang 
J, Gurry T, Williams R, Sikaroodi M, Fuchs M, Alm E, John B, Thacker LR, Riva A, Smith 
M, Taylor-Robinson SD, Gillevet PM. Fecal microbiota transplant from a rational stool 
donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017 
Dec;66(6):1727-1738. DOI: 10.1002/hep.29306
[58] Hefazi M, Patnaik MM, Hogan WJ, Litzow MR, Pardi DS, Khanna S. Safety and effi-
cacy of fecal microbiota transplant for recurrent Clostridium difficile infection in patients 
with cancer treated with cytotoxic chemotherapy: A single-institution retrospective 
case series. Mayo Clinic Proceedings. 2017 Nov;92(11):1617-1624. DOI: 10.1016/j.
mayocp.2017.08.016
[59] Fischer M, Khan M, Phelps EL, Safdar N, Misch EA, Kaur N, Kowsika SS, Smith JD, 
Kassam Z, Allegretti JR, Xu H, Kao DH. Fecal microbiota transplantation is safe and 
effective for the treatment of Clostridium difficile infection in solid organ transplant recipi-
ents. Gastroenterology. 2017;152(5 Supp 1):S1005
Gut Microbiota - Brain Axis82
[60] Baxter M, Colville A. Adverse events in faecal microbiota transplant: A review of the 
literature. The Journal of Hospital Infection. 2016 Feb;92(2):117-127. DOI: 10.1016/j.
jhin.2015.10.024
[61] Segal JP, Abbasi F, Kanagasundaram C, Hart A. Does the internet promote the unregu-
lated use of fecal microbiota transplantation: A potential public health issue? Clinical 
and Experimental Gastroenterology. 2018;11:179-183
[62] Samuel BP, Crumb TL, LaVigne HD. Nursing assassment for “do it yourself”fecal 
microbiota transplantation. Gastroenterology Nursing. 2016 Jan–Feb;39(1):60-62. DOI: 
10.1097/SGA.0000000000000142
[63] Hohmann EL, Ananthakrishnan AN, Deshpande V. Case records of the Massachusetts 
General Hospital. Case 25-2014. A 37-year-old man with ulcerative colitis and bloody 
diarrhea. The New England Journal of Medicine. 2014 Aug 14;371(7):668-675. DOI: 
10.1056/NEJMcpc1400842
[64] ClinicalTrials.gov. Identifier: NCT03026231. Characterization of Fecal Microbiome 
Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients. Houston: 
The University of Texas Health Science Center. https://clinicaltrials.gov/ct2/show/study/
NCT03026231?term=fecal+microbiota+transplantation&cond=%22Parkinson+Disease%
22&rank=1#contacts [Last Accessed: May 2, 2018]
[65] Scheperjans F, Pekkonen E, Kaakkola S, Auvinen P. Linking smoking, coffee, urate, 
and Parkinson's disease—A role for gut microbiota? Journal of Parkinson's Disease. 
2015;5(2):255-262. DOI: 10.3233/JPD-150557
[66] Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in 
Parkinson's disease. Lancet Neurology. 2015 Jun;14(6):625-639. DOI: 10.1016/S1474- 
4422(15)00007-1
[67] Derkinderen P, Shannon KM, Brundin P. Gut feelings about smoking and coffee 
in Parkinson's disease. Movement Disorders. 2014 Jul;29(8):976-979. DOI: 10.1002/
mds.25882
[68] Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson's disease. World Journal of 
Gastroenterology. 2015 Oct 7;21(37):10609-10620. DOI: 10.3748/wjg.v21.i37.10609
[69] Fang X. Potential role of gut microbiota and tissue barriers in Parkinson's disease 
and amyotrophic lateral sclerosis. The International Journal of Neuroscience. 2016 
Sep;126(9):771-776. DOI: 10.3109/00207454.2015.1096271
[70] Scheperjans F. Can microbiota research change our understanding of neurodegenerative 
diseases? Neurodegenerative Disease Management. 2016 Apr;6(2):81-85. DOI: 10.2217/
nmt-2015-0012
[71] de Vrieze J. Medical research. The promise of poop. Science. 2013 Aug 30;341(6149): 
954-957. DOI: 10.1126/science.341.6149.954
Fecal Microbiota Transplants as a Treatment Option for Parkinson’s Disease
http://dx.doi.org/10.5772/intechopen.78666
83

